Shiyao Innovation Unit Jushi Biologics Gets US FDA Approval for Mpox mRNA Vaccine Trial
Shiyao Innovation (300765) announced on August 10 that its controlling subsidiary Jushi Biologics has received approval from the US Food and Drug Administration to conduct clinical trials in the United States for SYS6037, an mpox vaccine built on an mRNA platform and developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences. The approval clears the way for the product's US clinical trial program to officially commence. The company made the disclosure without providing further details.
Shiyao Innovation (300765) announced on August 10 that its controlling subsidiary Jushi Biologics has recently received notification from the US Food and Drug Administration (FDA) that the clinical trial application for SYS6037 injection, an mpox mRNA vaccine developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved, allowing clinical trials to be conducted in the United States.
The vaccine employs an mRNA technology platform and targets the mpox virus. The approval means that clinical trial work for the product in the US can now officially get under way. Shiyao Innovation disclosed the above information in its announcement without providing further details.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 60/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.